Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington`s Disease and Presentations ...
(WorldNews Business)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 10, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it plans to advance SAGE-718, a novel, first-in-class, oxysterol-based positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors, to a Phase 2 placebo-controlled clinical trial in patients with Huntington´s disease (HD). The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an open-label cohort of patients with HD. In the...